Novartis has received the Food and Drug Administration’s accelerated approval for its Vijoice (alpelisib) for the treatment of severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS), a group of rare disorders associated with outgrowth of body parts.

The post FDA Approves Novartis’ Vijoice (Alpelisib) For PIK3CA-Related Overgrowth Spectrum appeared first on Latest Health & Medical News – Myhealthyclick.com.